A61K 51/1036
Against hormone receptors
Official title: {against hormone receptors}
A61K51/1036 (Against hormone receptors) appears on 17 US grants and 20 published applications in this corpus.
Search patents in A61K- Granted patents
- 17
- Published applications
- 20
- Assignees
- 12
- Inventors
- 52
- Latest grant
- 23 Dec 2025
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1992 | 1 | 0 |
| 1993 | 0 | 0 |
| 1994 | 0 | 0 |
| 1995 | 0 | 0 |
| 1996 | 0 | 0 |
| 1997 | 1 | 0 |
| 1998 | 3 | 0 |
| 1999 | 2 | 0 |
| 2000 | 0 | 0 |
| 2001 | 1 | 0 |
| 2002 | 0 | 1 |
| 2003 | 0 | 0 |
| 2004 | 0 | 2 |
| 2005 | 0 | 0 |
| 2006 | 0 | 1 |
| 2007 | 0 | 0 |
| 2008 | 0 | 0 |
| 2009 | 0 | 1 |
| 2010 | 1 | 0 |
| 2011 | 0 | 1 |
| 2012 | 0 | 0 |
| 2013 | 1 | 0 |
| 2014 | 0 | 1 |
| 2015 | 0 | 0 |
| 2016 | 0 | 0 |
| 2017 | 0 | 3 |
| 2018 | 0 | 0 |
| 2019 | 2 | 0 |
| 2020 | 0 | 0 |
| 2021 | 0 | 2 |
| 2022 | 2 | 2 |
| 2023 | 0 | 3 |
| 2024 | 0 | 1 |
| 2025 | 3 | 0 |
| 2026 | 0 | 2 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Structural optimization method to improve the theranostic performance of peptide receptor-targeted radionuclide therapy for cancers23 Dec 2025US 12,502,442 B2University of Iowa Research Foundation
- Cysteine linked nanobody dimers12 Aug 2025US 12,384,835 B2Ablynx N. V.
- Structural optimization method to improve the theranostic performance of peptide receptor-targeted radionuclide therapy for cancers24 Jun 2025US 12,337,042 B2University of Iowa Research Foundation
- Actinium-225 and checkpoint inhibitor combination therapy20 Sep 2022US 11,446,401 B2Fusion Pharmaceuticals Inc.
- Cysteine linked nanobody dimers30 Aug 2022US 11,426,468 B2Ablynx N. V.
- Mutant fab fragment for obtaining site-specific mono-or bifunctionalised conjugates10 Sep 2026US 2026/0265367 A1
- Anti-tshr antibodies and uses thereof10 Sep 2026US 2026/0265387 A1Ethyreal Bio, Inc.
- Structural Optimization Method to Improve the Theranostic Performance of Peptide Receptor-Targeted Radionuclide Therapy for Cancers7 Nov 2024US 2024/0366816 A1University of Iowa Research Foundation
- Radioimmunoconjugates and checkpoint inhibitor combination therapy31 Aug 2023US 2023/0270895 A1Fusion Pharmaceuticals Inc.
- Cysteine linked nanobody dimers6 Jul 2023US 2023/0211006 A1Ablynx N. V.
Most cited
By later US patents
- Lymphographic and organ imaging method and kit129US 5,101,827 AImmunomedics, Inc. · 1992
- Method for imaging and treating organs and tissues124US 5,697,902 AImmunomedics, Inc. · 1997
- Method and kit for imaging and treating organs and tissues110US 6,331,175 B1Immunomedics, Inc. · 2001
- Method for imaging and treating organs and tissues47US 5,776,093 AImmunomedics, Inc. · 1998
- Method and kit for imaging and treating organs and tissues42US 5,776,094 AImmunomedics, Inc. · 1998